ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 365,70
0,12%
Dow Jones
43 449,90
-0,61%
DAX
20 246,37
-0,33%
Brent Oil
73,015
-0,12%
Bitcoin
103 711,19
-2,30%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Longeveron Inc (LGVN) Cours

Longeveron Inc

Longeveron Inc (LGVN)

NASDAQ
1,78
-0,04
(-2,20%)
Fermé 18 Décembre 10:00PM
Retardé de 15 minutes
1,79
0,01
(0,56%)
Après les heures de négociation: 1:49AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
1,79
Prix Achat
1,78
Prix Vente
1,82
Volume échangé
338 764
1,75 Fourchette du Jour 1,835
0,7707 Plage de 52 semaines 21,70
Cap du marché
26,558M
Clôture Veille
1,82
Ouverture
1,80
Dernière Transaction
40
@
1.818
Dernière heure de transaction
Volume financier
US$ 606 339
VWAP
1,7899
Volume moyen (3 m)
479 490
Actions en circulation
14 836 775
Rendement du Dividende
-
Ratio Cours sur Bénéfices
0,00
Bénéfice par action (BPA)
-
Chiffre d'affairess
709k
Bénéfice net
-22,21M

À propos de Longeveron Inc

Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
/www.longeveron.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Longeveron Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker LGVN. Le dernier cours de clôture d'Longeveron était de US$1,82. Au cours de la dernière année, les actions de Longeveron ont été négociées dans une fourchette de prix de US$ 0,7707 à US$ 21,70.

Longeveron compte actuellement 14 836 775 actions en circulation. La capitalisation boursière d'Longeveron est de US$27,00 million.

LGVN Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

12 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

12 Novembre 2024
Edgar (US Regulatory)

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal...

12 Novembre 2024
GlobeNewswire Inc.

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

11 Novembre 2024
GlobeNewswire Inc.

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

04 Novembre 2024
GlobeNewswire Inc.

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD)Lomecel-B™ capacity to inhibit MMP14 correlates with...

29 Octobre 2024
GlobeNewswire Inc.

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none...

27 Octobre 2024
GlobeNewswire Inc.

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its submission entitled...

14 Octobre 2024
GlobeNewswire Inc.

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

09 Octobre 2024
GlobeNewswire Inc.

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

07 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.29-13.94230769232.082.081.7752200881.88663609CS
4-0.13-6.770833333331.922.161.7353222581.95352132CS
12-0.2-10.05025125631.992.48431.7354794902.05314769CS
26-1.13-38.6986301372.926.391.4627111113.48822862CS
52-18.71-91.268292682920.521.70.770734786823.12995531CS
156-154.81-98.8569604087156.6192.50.7707175772741.57738832CS
260-13.01-87.905405405414.84500.7707203609192.77162113CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NUKKNukkleus Inc
US$ 11,655
(738,49%)
174,07M
PRTGPortage Biotech Inc
US$ 8,8678
(172,86%)
36,23M
OPTXSyntec Optics Holdings Inc
US$ 3,55
(99,44%)
92,44M
PTPIPetros Pharmaceuticals Inc
US$ 0,4976
(86,37%)
63,38M
LUXHLuxUrban Hotels Inc
US$ 0,849899
(59,67%)
29,51M
VCNXVaccinex Inc
US$ 1,41
(-61,37%)
758,95k
TNYATenaya Therapeutics Inc
US$ 1,395
(-51,56%)
42,45M
ORKTOrangeKloud Technology Inc
US$ 2,14
(-41,85%)
2,29M
RVPHReviva Pharmaceuticals Holdings Inc
US$ 1,395
(-39,35%)
18,16M
DBGIDigital Brands Group Inc
US$ 2,46
(-37,88%)
805,23k
RIMEAlgorhythm Holdings Inc
US$ 0,0877
(8,27%)
1,13B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,335
(-36,79%)
1,02B
GOEVCanoo Inc
US$ 0,118
(7,08%)
388,43M
NVDANVIDIA Corporation
US$ 130,39
(-1,22%)
259,4M
XTIAXTI Aerospace Inc
US$ 0,0442
(8,33%)
222,55M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
LGVN
Longeveron
NASDAQ
SYTAW
Siyata Mobile
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés